Advertisement

Pharmaceutisch Weekblad

, Volume 2, Issue 1, pp 853–858 | Cite as

De toepassing van theofyllinepreparaten met vertraagde afgifte

  • J. Zuidema
  • R. J. van Bever
  • F. W. H. M. Merkus
Overzichtsartikelen

Abstract

Sustained release preparations are expensive and experience with them is but little. A clear indication is needed for the application of sustained release preparations. After administration of quickly releasing preparations to patients with a rapid elimination, risk occurs for too large differences in peak and trough concentrations. Nevertheless a medication schedule of twice a day is desirable in view of the patient compliance. The application of sustained release preparations twice a day is justified for patients with an elimination half-life less than eight hours. This is generally the case with children. For adults it can be calculated that sustained release preparations are only indicated if more than 10, resp. 15 mg per kg body weight per day is needed to obtain a serum theophylline concentration of 10, resp. 15μg/ml in steady state.

Promising preparations, available on the American market, are Slophylline®, Theolair sr® and Theodur®4.

Keywords

Public Health Body Weight Internal Medicine Steady State Theophylline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. A theophylline symposium: The current role of oral theophylline derivatives in respiratory medicine. Montreux (1979)J. Intern. Med. Res. 7, Suppl. 1–113, 19 papers.Google Scholar
  2. Chrzanowski, F. A., P. J. Niebergall, R. L. Mayock, J. M. Taubin enE. T. Sugita (1977)Clin. Pharmacol. Therap. 22, 188–195.Google Scholar
  3. Clark, T. J. H., enS. Godfrey (1977)Asthma, Ist ed. Chapman and Hall, London, 241–250.Google Scholar
  4. Dasta, J., J. M. Mirtallo enH. Altman (1979)Am. J. Hosp. Pharm. 36, 613–617.Google Scholar
  5. Falliers, C. J. (1978)Angiology 29, 852–856.Google Scholar
  6. Goldberg, P. B., M. A. Gonzales, L. Gogenola enF. Leffert (1978)Am. Rev. Respirat. Diseases 117, 295.Google Scholar
  7. Hendeles, L., M. Weinberger enL. Bighley (1977)Am. J. Hosp. Pharm. 34, 525–527.Google Scholar
  8. Jonkman, J. H. G. (1979)Pharm. Weekblad 114, 629–648.Google Scholar
  9. Jusko, W. J., M. J. Gardner, A. Mangione, J. J. Schentag, J. R. Koup enJ. W. Vance (1979)J. Pharm. Sci. 68, 1358–1365.Google Scholar
  10. Koup, J. R., J. J. Schentag, J. W. Vance, P. H. Kuritzky, D. R. Pysczynski enW. J. Jusko (1976)Am. J. Hosp. Pharm. 33, 949–956.Google Scholar
  11. Koysooko, R. A. (1976)Dissertation abstr. intern. B. 36, 3319–3320.Google Scholar
  12. Lagas, M., enJ. H. Glerum (1977)Pharm. Weekblad 112, 97–110.Google Scholar
  13. Lawyer, C., N. Gerber, J. Morris, R. Rogers enE. Bardana (1979)Am. Rev. Respiratory Diseases 119, 73.Google Scholar
  14. Mitenko, P. A., enR. I. Ogilvie (1973)Clin. Pharmacol. Therap. 14, 509–513;Ibidem (1974)16, 720–726.Google Scholar
  15. Nell, P. A., M. Schwarz enR. J. Greene (1978)J. Allergy Clin. Immunol. 61, 174.Google Scholar
  16. Russel, C. J., R. K. Elwood, C. Kinney enD. G. McDevitt (1979)Proc. Brit. Pharm. Soc. Jan. 1979, C. 17.Google Scholar
  17. Soeterboek, A. M., enJ. H. G. Jonkman (1979) In:The serum concentration of drugs (Merkus, F. W. H. M., Ed.) Excerpta Medica, Amsterdam-Oxford-Princeton, 250–259.Google Scholar
  18. Spangler, D. L., D. D. Kalof, F. L. Bloom enH. J. Wittig (1978)Ann. Allergy 40, 6–11.Google Scholar
  19. Svedmyr, N. (1977)Scand. J. Respirat. Diseases Suppl. 101, 13–25.Google Scholar
  20. Tjandramaga, T. B., R. Verbesselt enP. J. Schepper (1979)Current Med. Res. Op. 6, 142S-150S.Google Scholar
  21. Weinberger, M. W., enL. Hendeles (1976)Am. J. Hosp. Pharm. 33, 1071–1080.Google Scholar
  22. Weinberger, M., enL. Hendeles (1979)Current Med. Res. Op. 6, 116S-131S.Google Scholar
  23. Weinberger, M., L. Hendeles enL. Bighley (1978)New Engl. J. Med. 299, 852–857.Google Scholar
  24. Welling, P. G., L. L. Lyons, W. A. Craig enG. A. Trochta (1975)Clin. Pharmacol. Therap. 17, 475–480.Google Scholar
  25. Ziment, I. (1978)Respiratory pharmacology and therapeutics, ist ed. W. B. Saunders Cy, Philadelphia-London-Toronto, 105–146.Google Scholar
  26. Zuidema, J. (1978)Biofarmaceutische en farmacokinetische aspecten van theofylline en acefylline. Proefschrift, Amsterdam.Google Scholar
  27. Zuidema, J., enF. W. H. M. Merkus (1979)Current Med. Res. Op. 6, 14S-25S.Google Scholar
  28. Zuidema, J., W. Reunierse, R. H. A. Mulkens enF. W. H. M. Merkus (1976)Pharm. Weekblad III, 609–620.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1980

Authors and Affiliations

  • J. Zuidema
    • 1
  • R. J. van Bever
    • 2
  • F. W. H. M. Merkus
    • 1
    • 2
  1. 1.Laboratorium voor Artsenijbereidkunde der Universiteit van Amsterdamtv Amsterdam
  2. 2.R.K. Ziekenhuisbk Sittard

Personalised recommendations

Cite article

Buy options